• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊髓和延髓肌肉萎缩症(SBMA)的发病机制、生物标志物和治疗方法。

Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA).

机构信息

Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.

出版信息

J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1085-1091. doi: 10.1136/jnnp-2020-322949.

DOI:10.1136/jnnp-2020-322949
PMID:32934110
Abstract

Spinal and bulbar muscular atrophy (SBMA) is a hereditary neuromuscular disorder caused by CAG trinucleotide expansion in the gene encoding the androgen receptor (). In the central nervous system, lower motor neurons are selectively affected, whereas pathology of patients and animal models also indicates involvement of skeletal muscle including loss of fast-twitch type 2 fibres and increased slow-twitch type 1 fibres, together with a glycolytic-to-oxidative metabolic switch. Evaluation of muscle and fat using MRI, in addition to biochemical indices such as serum creatinine level, are promising biomarkers to track the disease progression. The serum level of creatinine starts to decrease before the onset of muscle weakness, followed by the emergence of hand tremor, a prodromal sign of the disease. Androgen-dependent nuclear accumulation of the polyglutamine-expanded AR is an essential step in the pathogenesis, providing therapeutic opportunities via hormonal manipulation and gene silencing with antisense oligonucleotides. Animal studies also suggest that hyperactivation of Src, alteration of autophagy and a mitochondrial deficit underlie the neuromuscular degeneration in SBMA and provide alternative therapeutic targets.

摘要

脊髓延髓肌肉萎缩症(SBMA)是一种遗传性神经肌肉疾病,由雄激素受体()基因中编码的 CAG 三核苷酸扩展引起。在中枢神经系统中,下运动神经元被选择性地影响,而患者和动物模型的病理学也表明骨骼肌的参与,包括快肌 II 型纤维的丧失和慢肌 I 型纤维的增加,以及糖酵解到氧化代谢的转换。使用 MRI 评估肌肉和脂肪,以及血清肌酐水平等生化指标,是跟踪疾病进展的有前途的生物标志物。血清肌酐水平在肌肉无力出现之前开始下降,随后出现手部震颤,这是疾病的前驱症状。雄激素依赖性核内聚谷氨酰胺扩展的 AR 积累是发病机制中的一个重要步骤,通过激素操作和反义寡核苷酸的基因沉默提供了治疗机会。动物研究还表明,Src 的过度激活、自噬的改变和线粒体缺陷是 SBMA 中神经肌肉退化的基础,并提供了替代的治疗靶点。

相似文献

1
Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA).脊髓和延髓肌肉萎缩症(SBMA)的发病机制、生物标志物和治疗方法。
J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1085-1091. doi: 10.1136/jnnp-2020-322949.
2
X-Linked Spinal and Bulbar Muscular Atrophy: From Clinical Genetic Features and Molecular Pathology to Mechanisms Underlying Disease Toxicity.X 连锁脊髓性肌萎缩症:从临床遗传特征和分子病理学到疾病毒性的潜在机制。
Adv Exp Med Biol. 2018;1049:103-133. doi: 10.1007/978-3-319-71779-1_5.
3
Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy.脊髓延髓肌肉萎缩症的分子病理生理学与疾病修饰疗法
Arch Neurol. 2012 Apr;69(4):436-40. doi: 10.1001/archneurol.2011.2308. Epub 2011 Dec 12.
4
[Molecular-targeted therapies for spinal and bulbar muscular atrophy].[脊髓延髓肌肉萎缩症的分子靶向治疗]
Rinsho Shinkeigaku. 2009 Nov;49(11):917-20. doi: 10.5692/clinicalneurol.49.917.
5
Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet.糖酵解型向氧化型纤维类型转换以及mTOR信号激活是高脂饮食改变的脊髓性肌萎缩症肌肉的早期特征。
Acta Neuropathol. 2016 Jul;132(1):127-44. doi: 10.1007/s00401-016-1550-4. Epub 2016 Mar 12.
6
Deterioration of muscle force and contractile characteristics are early pathological events in spinal and bulbar muscular atrophy mice.肌肉力量和收缩特性的恶化是脊髓性肌萎缩症和延髓性肌肉萎缩症小鼠的早期病理事件。
Dis Model Mech. 2020 May 26;13(5):dmm042424. doi: 10.1242/dmm.042424.
7
In Vitro and In Vivo Modeling of Spinal and Bulbar Muscular Atrophy.脊髓延髓肌肉萎缩的体外和体内模型
J Mol Neurosci. 2016 Mar;58(3):365-73. doi: 10.1007/s12031-015-0677-4. Epub 2015 Nov 27.
8
Molecular pathogenesis of spinal bulbar muscular atrophy (Kennedy's disease) and avenues for treatment.脊髓延髓肌萎缩症(肯尼迪病)的分子发病机制与治疗途径。
Curr Opin Neurol. 2020 Oct;33(5):629-634. doi: 10.1097/WCO.0000000000000856.
9
Nucleic Acid-Based Therapeutic Approach for Spinal and Bulbar Muscular Atrophy and Related Neurological Disorders.基于核酸的脊髓性肌萎缩症和相关神经疾病治疗方法。
Genes (Basel). 2022 Jan 5;13(1):109. doi: 10.3390/genes13010109.
10
Introduction to the Special Issue on Spinal and Bulbar Muscular Atrophy.脊髓延髓性肌萎缩专题介绍
J Mol Neurosci. 2016 Mar;58(3):313-6. doi: 10.1007/s12031-016-0720-0. Epub 2016 Feb 13.

引用本文的文献

1
Kv3 channel agonist ameliorates the phenotype of a mouse model of amyotrophic lateral sclerosis.Kv3通道激动剂改善肌萎缩侧索硬化症小鼠模型的表型。
Acta Neuropathol Commun. 2025 Jul 14;13(1):153. doi: 10.1186/s40478-025-02067-z.
2
Unveiling the effect of curcumin on ion channels of SBMA motoneuron-derived cells and human IPSC-derived neurons: initial electrophysiological findings.揭示姜黄素对脊髓性肌萎缩症运动神经元衍生细胞和人诱导多能干细胞衍生神经元离子通道的影响:初步电生理研究结果。
Eur Biophys J. 2025 Jul 7. doi: 10.1007/s00249-025-01780-w.
3
Dysregulated synaptic gene expression in oligodendrocytes of spinal and bulbar muscular atrophy.
脊髓延髓肌肉萎缩症少突胶质细胞中突触基因表达失调
JCI Insight. 2025 Jun 23;10(12). doi: 10.1172/jci.insight.182123.
4
Functional Outcome Measures to Optimize Drug Development in Spinal and Bulbar Muscular Atrophy: Results From a Meta-Analysis of the Global SBMA Dataset.功能结果测量优化脊髓和延髓肌肉萎缩症的药物开发:来自全球 SBMA 数据集的荟萃分析结果。
Neurology. 2024 Dec 24;103(12):e210088. doi: 10.1212/WNL.0000000000210088. Epub 2024 Nov 26.
5
One case of spinal bulbar muscular atrophy misdiagnosed as polymyositis: Case report.一例误诊为多发性肌炎的脊髓性延髓肌萎缩症:病例报告。
Medicine (Baltimore). 2024 Sep 27;103(39):e39169. doi: 10.1097/MD.0000000000039169.
6
Pattern of pareses in 5q-spinal muscular atrophy.5q型脊髓性肌萎缩症中的瘫痪模式
Ther Adv Neurol Disord. 2024 Aug 27;17:17562864241263420. doi: 10.1177/17562864241263420. eCollection 2024.
7
Patient-Reported Impact of Symptoms in Spinal and Bulbar Muscular Atrophy.患者报告的脊髓延髓肌肉萎缩症状的影响
Neurol Clin Pract. 2023 Dec;13(6):e200213. doi: 10.1212/CPJ.0000000000200213. Epub 2023 Oct 31.
8
Central neurodegeneration in Kennedy's disease accompanies peripheral motor dysfunction.肯尼迪病的中枢神经退行性变伴随着周围运动功能障碍。
Sci Rep. 2024 Aug 7;14(1):18331. doi: 10.1038/s41598-024-69393-5.
9
Protein biomarker signature in patients with spinal and bulbar muscular atrophy.脊髓性肌萎缩症患者的蛋白质生物标志物特征。
JCI Insight. 2024 May 30;9(13):e176383. doi: 10.1172/jci.insight.176383.
10
Insights into spinal muscular atrophy from molecular biomarkers.从分子生物标志物看脊髓性肌萎缩症
Neural Regen Res. 2025 Jul 1;20(7):1849-1863. doi: 10.4103/NRR.NRR-D-24-00067. Epub 2024 Jun 26.